Loading…
Kura Oncology, Inc.
Kura Oncology, Inc. (KURA) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in San Diego, United States and has 260 employees. The company is worth $877.15M. Revenue was $67.48M in fiscal 2025, up 25.2% from the year before. It reported a net loss of $278.67M. The share price is 29.1% below its 52-week high of $13.90. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Cliff Asness (AQR Capital Management), at $34.3M. In that quarter, 1 of them opened or added to the position and 2 reduced it. Over the last 30 days, company insiders sold $1.26M of its stock on the open market and bought none. $599.35K of those sales were scheduled in advance under 10b5-1 plans.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -35.0% over 5Y.
today you would have $552.98▼ -44.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 11 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $10.39 | $8.71 | $14.38 | $12.41 | $14.00 | $32.66 | $13.75 | $14.04 | $15.30 | $5.90 | $8.40 | |
| P/S | — | 13.6x | 13.1x | — | — | — | — | — | — | — | — | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| BBNXBeta Bionics, Inc. | $16.35 | — | 2.9x | 0.00% | -26.16% | $882.02M |
| MGTXMeiraGTx Holdings plc | $9.28 | 10.3x | 4.1x | 0.00% | 72.17% | $891.28M |
| ANROAlto Neuroscience, Inc. | $21.94 | — | 3.5x | 0.00% | -49.17% | $860.97M |
| CRVSCorvus Pharmaceuticals, Inc. | $10.65 |
| P/B |
| 2.8x |
| 5.3x |
| 1.7x |
| 2.8x |
| 2.0x |
| 1.8x |
| 3.5x |
| 2.9x |
| 3.3x |
| 6.4x |
| 2.2x |
| 2.2x |
| EPS | -$3.18 | -$2.02 | -$2.08 | -$2.03 | -$1.97 | -$1.69 | -$1.51 | -$1.72 | -$1.52 | -$1.47 | -$2.28 |
| Profit margin | — | -412.95% | -322.89% | — | — | — | — | — | — | — | — | — |
| ROE | -37.55% | -160.03% | -42.06% | -38.42% | -32.32% | -25.75% | -14.67% | -28.86% | -37.55% | -44.37% | -48.46% | -27.56% |
Median of the years shown; P/E years above 200x are left out.
| — |
| 4.0x |
| 0.00% |
| -35.43% |
| $895.89M |
| SLBTSL Science Holding Ltd | $1.53 | — | 1.2x | 0.00% | — | $857.96M |
| JBIOJade Biosciences, Inc. | $13.47 | — | 1.9x | 0.00% | — | $856.66M |